Previous 10 | Next 10 |
Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success. CAPTISOL is at the center of Ligand's current revenue-generating business operations. The company's growth prospec...
Two large pharma partners reach clinical-development milestones with OmniAb-derived antibody programs and Ligand earns $4.5 million in milestone payments CStone Pharmaceuticals announces China NDA submission and data for its OmniAb-derived antibody to treat non-small cell lung...
Captisol-enabled ™ product is stable at room temperature for timely administration at the point of patient care Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U....
Image source: The Motley Fool. Ligand Pharmaceuticals Inc (NASDAQ: LGND) Q3 2020 Earnings Call Oct 30, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Inc (LGND) Q3 2020 Earnings Call Transcri...
Ligand Pharmaceuticals Incorporated (LGND) Q3 2020 Earnings Conference Call October 30, 2020 8:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance & Chief Financial Officer Matt Foehr ...
Ligand Pharmaceuticals ([[LGND]] -3.6%) Q3 results:Revenues: $41.8M (+68.7%); Royalties revenue: $9.0M (-7.9%); Captisol sales: $23.4M (+241.5%); Contract revenue: $9.5M (+15.4%).Net Loss: ($6.7M) (-56.1%); Loss Per Share: ($0.42) (-48.2%); Non-GAAP Net Income: $17.5M (+83.4%); Non-...
The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2020 Q3 earnings call. For further details see: Ligand Pharmaceuticals Incorporated 2020 Q3 - Results - Earnings Call Presentation
Ligand Pharmaceuticals (LGND): Q3 Non-GAAP EPS of $1.04 beats by $0.06; GAAP EPS of -$0.42 misses by $0.95.Revenue of $41.85M (+68.7% Y/Y) misses by $3.24M.Press Release For further details see: Ligand Pharmaceuticals EPS beats by $0.06, misses on revenue
Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand ...
Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q3 earnings results on Friday, October 30th, before market open.The consensus EPS Estimate is $0.98 (+100.0% Y/Y) and the consensus Revenue Estimate is $45.09M (+81.7% Y/Y).Over the last 2 years, LGND has beaten EPS estimates 100% ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...